Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Gefitinib + TAK-701|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gefitinib||Iressa||ZD1839||EGFR Inhibitor (Pan) 47 EGFR Inhibitor 1st gen 3||Iressa (gefitinib) is a first-generation EGFR inhibitor that binds EGFR and inhibits downstream signaling, potentially resulting in decreased growth of tumors with EGFR activation (PMID: 26980062, PMID: 25302162, PMID: 15284455). Iressa (gefitinib) is FDA approved for use in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R (FDA.gov).|
|TAK-701||HuL2G7||HGF Antibody 4||TAK-701 is a monoclonal antibody that targets HGF and prevents its binding to MET, resulting in decreased activation of HGF/MET signaling and potentially resulting in increased tumor cell death (PMID: 24019233).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|